Fig 2: Representative immunohistochemical staining of RAP80 positive expression in breast cancer tissue and paired normal breast tissue.Note: Positive nucleus staining of RAP80 in the paired normal breast mammary epithelium (A, B), RAP80 expression in ductal carcinoma in situ (C), and invasive ductal cancer (D); original magnification, all ×200.

Fig 3: RAP80 siRNA transfection upregulated the expression of apoptotic proteins in MCF-7 cells.Notes: Western blot results showed that the siRNA transfection upregulated the protein expression of Caspase-3, cleaved Caspase-3, Apaf-1, Cytochrome C, Bax, and Fas, and it downregulated the mRNA and protein expression of Bcl-2. Protein levels analyzed by Western blot also confirmed this result (A–G). Data are presented as mean ± SD of three independent experiments, *P<0.05 vs MCF-7 siRAP80 group.

Fig 4: RAP80 siRNA transfection decreased the invasive or migrating ability of MCF-7 breast cancer cells.Notes: Transwell migration assay shows the migrating ability of wild-type MCF-7 (A), MCF-7-siNC (B), and MCF-7 siRAP80 (C) at 72 hours after transfection. (G) Number of cells migrating onto the lower surfaces of the filter was counted. The transwell migration assay shows the invasive ability of wild-type MCF-7 (D), MCF-7-siNC (E), and MCF-7 siRAP80 (F) at 72 hours after transfection (H). Number of cells invading onto the lower surfaces of the filter was counted. Data are presented as mean ± SD of three independent experiments, *P<0.05 vs MCF-7 siRAP80 group.Abbreviation: NC, normal control.

Fig 5: The Effect of RAP80 siRNA transfection on cell proliferation by MTT in wild-type MCF-7 or MCF-7 RAP80 siRNA.Notes: The survival rate of both cells decreased in a dose-dependent manner and the IC50 value for cisplatin in MCF-7 RAP80 siRNA cells was 0.83 µg/mL, and 1.69 µg/mL in wild-type MCF-7. Cell viability was measured by MTT; n=3 for each data point.